Previous article
Avoiding Racist and Judgmental Clinical Documentation: Helping to Achieve Health Equity
Jun 2024
Next article
Oseltamivir Does Not Reduce the Likelihood of Hospitalization in Adults
STEPS
New Drug Reviews

RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory Syncytial Virus Infection

Matthew Nodelman, MD,
A. Miles Scott, DO,
Prisma Health/University of South Carolina School of Medicine–Columbia, Columbia, South Carolina

American Family Physician. 2024;109(6):578-579.

Author disclosure: No relevant financial relationships.

Address correspondence to Matthew Nodelman, MD, at matthew.nodelman@prismahealth.org. Reprints are not available from the authors.

Author disclosure: No relevant financial relationships.

  1. 1.DailyMed. Drug label information. Abrysvo—respiratory syncytial virus vaccine kit. Accessed January 10, 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be18292e-b1a2-4815-a0ed-003efaa6bea3#leftmenu
  2. 2.DailyMed. Drug label information. Beyfortus—nirsevimab injection. Accessed January 10, 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f08fa60-f674-432d-801b-1f9514bd9b39#ID_f92d84a4-7a21-4a02-acf9-9d01dda07f0a
  3. 3.Drysdale SB, Cathie K, Flamein F, et al.; HARMONIE Study Group. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425-2435.
  4. 4.Hammitt LL, Dagan R, Yuan Y, et al.; MELODY Study Group. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837-846.
  5. 5.Kampmann B, Madhi SA, Munjal I, et al.; MATISSE Study Group. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451-1464.
  6. 6.American Academy of Pediatrics. Patient care. Nirsevimab (Beyfortus) product & ordering information. Updated October 11, 2023. Accessed January 10, 2024. https://www.aap.org/en/patient-care/respiratory-syncytial-virus-rsv-prevention/nirsevimab-beyfortus-product--ordering-information/

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

Previous article
Avoiding Racist and Judgmental Clinical Documentation: Helping to Achieve Health Equity
Jun 2024
Next article
Oseltamivir Does Not Reduce the Likelihood of Hospitalization in Adults

Current issue

May 2026

May 2026

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.